United States · 
Who invested in ImmusanT?
ImmusanT's investors include Vatera Healthcare Partners, Arch and Vatera.
201220132014201520162017
$20MSeries A$12MSeries B$40MSeries C
United States · Series C startup
Who invested in ImmusanT
Funding summaryUpdated 26 Oct 2026
$72Mraised across 3 rounds since 2011, from 3 sources
$20MSeries A$12MSeries B$40MSeries C
- Latest round
- Series C, $40MNov 2017
- Step-upi
- 3.3×
- Investors
- 3
The funding story
Each circle is a round, placed by date and sized by amount. The line above is the running total.
- First round
- Series A, $20M Dec 2011
- Biggest round
- $40M Series C · Nov 2017
- Usual gap between rounds
- 3 years the median of 2
The rounds
- Nov 2017
- Dec 2014Series B$12M1 returning
From a historical funding recordSEC filing: $13M sold, first sale Dec 2014
- Dec 2011
Founders and team
From ImmusanT's own website and the SEC filings it signed: 3 on the team.
- Kaela GoldsteinSenior Research Scientist
- One Kendall SquareOffice Manager
- Leslie WilliamsExecutive Officer, Directori
On the board, as filediCeclia GonzaloKevin FerroSteven GillisThomas DanielThomas Koestler
Who was in which round
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
Everyone who backed them
Missing a round, or an investor who was in one? Tell us.
Quick answers about ImmusanT
How much has ImmusanT raised?
ImmusanT has raised $72M across 3 rounds since 2011.
When did ImmusanT last raise?
ImmusanT's most recent round was a Series C of $40M in Nov 2017.
What was ImmusanT's biggest round?
Its most recent round, $40M in Nov 2017, is also its largest on record.
Who backed ImmusanT first?
ImmusanT's first round on record, in Dec 2011, was backed by Vatera Healthcare Partners.
What stage is ImmusanT at?
ImmusanT's latest named round is a Series C, in Nov 2017.
Where is ImmusanT based?
ImmusanT is based in the United States.
Companies like ImmusanT
In the same sector, and raised in the last eighteen months.
Find investors like these
Search every investor by what they have actually funded, then narrow to your stage and market. Free.